Top Markets
#1 Nesa Nesa +820.50%
#2 Cortex Cortex +68.91%
#3 Kinesis Silver Kinesis Silver +57.40%
#4 Merlin's Seal BTC Merlin's Seal BTC +45.66%
#5 QuantixAI QuantixAI +24.05%
#6 EXOD EXOD +22.78%
#7 Cash Cat Cash Cat +20.46%
#8 OpenEden OpenEden +19.61%
#9 Palladium Network Palladium Network +18.94%
#10 Instadapp Instadapp +16.15%
Coin of the day
Nesa Nesa
Pengaturan
Bahasa
BAHASA INDONESIA
Mata uang
USD
Tema
InflaRx N.V. InflaRx N.V.

InflaRx N.V.

IF0
Peringkat dalam Saham #19690
InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing... InflaRx N.V. operates as a clinical-stage biopharmaceutical firm, specializing in the identification and advancement of C5a inhibitors. Their primary operational territories are Germany and the United States. C5a, an inflammatory mediator, plays a critical role in the advancement of various autoimmune and inflammatory conditions. The company's leading therapeutic candidate, vilobelimab, is an innovative, intravenously administered, first-in-class monoclonal antibody designed to target C5a. This compound has successfully completed Phase III clinical trials for treating hidradenitis suppurativa, a severe, chronic, and debilitating systemic inflammatory skin disease. Furthermore, vilobelimab is undergoing Phase II trials for anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disorder. An exploratory Phase IIa study is also underway for pyoderma gangraenosum, a persistent inflammatory skin condition. Additionally, vilobelimab is in Phase II clinical development for locally advanced or metastatic cutaneous squamous cell carcinoma that is resistant or refractory to PD-1/PD-L1 inhibitors. Beyond their lead candidate, InflaRx is developing INF904, an oral small molecule drug, intended for currently undisclosed chronic inflammatory and autoimmune diseases. Another pipeline asset, IFX002, is in preclinical stages, targeting chronic inflammation and autoimmune diseases. The company has established strategic alliances, including a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration and supply agreement with Merck & Co. Inc. Established in 2007, the company was initially known as Fireman B.V. before adopting the name InflaRx N.V. in 2017. Its corporate headquarters are located in Jena, Germany.
Harga Saham
$3.49
Terakhir disinkronkan: 2022-08-12
Kapitalisasi Pasar
$154.10M
Perubahan (1 hari)
12.28%
Perubahan (1 tahun)
0.00%
Negara
DE
Perdagangan InflaRx N.V. (IF0)

Kategori

Healthcare
Riwayat harga saham InflaRx N.V. (IF0)
Harga penutupan tertinggi: $2.95 pada 2022-08-01

Harga penutupan terendah: $3.75 pada 2019-12-01
Riwayat harga saham InflaRx N.V. dari 2019 hingga 2026
Performa harga saham tahunan
Tahun Performa
2022 -31.72%
2021 -9.75%
2020 27.64%
2019 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $553.09 42.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.02K 44.02%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $158.64 541.49%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.62 -12.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $768.63 6.83%
CH